Results 71 to 80 of about 20,748 (167)
Non-driver mutations in myeloproliferative neoplasm-associated myelofibrosis
Journal of Hematology & Oncology, 2017 We studied non-driver mutations in 62 subjects with myeloproliferative neoplasm (MPN)-associated myelofibrosis upon diagnosis, including 45 subjects with primary myelofibrosis (PMF) and 17 with post-polycythemia vera or post-essential thrombocythemia ...
Bing Li +11 more
doaj +1 more source
Multifacet Roles of Cellular Senescence in Cancer: Mechanisms and Therapeutic Implications
MedComm – Oncology, Volume 5, Issue 1, March 2026.Cellular senescence shapes tumor progression through both antitumor and protumor mechanisms. Senescence triggered by telomere shortening restricts malignant transformation and limits tumor cell proliferation, while the senescence‐associated secretory phenotype (SASP) secretion enhances antitumor immunity by activating cytotoxic T cells.
Huajie Mao +5 more
wiley +1 more source
eJHaemIntroduction Myelofibrosis is characterized by debilitating constitutional symptoms and anemia, which negatively impact survival and quality of life.
Ruben A. Mesa +11 more
doaj +1 more source
The JAK/STAT Pathway in Cancer: From Molecular Mechanisms to Clinical Applications
MedComm – Oncology, Volume 5, Issue 1, March 2026.Dysregulated JAK/STAT signaling and related genetic mutations are strongly associated with cancer progression, including promoting tumor proliferation, suppressing apoptosis, inducing immune suppression, participating in drug resistance. Based on the function of the JAK/STAT pathway in disease pathogenesis, numerous agents targeting the JAK/STAT ...
Yixing Liao +10 more
wiley +1 more source
Small, Volume 22, Issue 18, 25 March 2026.We introduce a versatile 3D platform that recreates key physical and biological features of the human bone marrow. By integrating tunable silk biomaterials, stromal cells, and human hematopoietic progenitors, the model captures both healthy and diseased microenvironments, analysis of blood formation, and its disruption in pathological conditions ...
Christian A. Di Buduo +13 more
wiley +1 more source
Acute massive myelofibrosis with acutelymphoblastic leukemia
Turkish Journal of Hematology, 2009 Acute myelofibrosis is characterized by pancytopenia of sudden onset, megakaryocytic hyperplasia, extensive bone marrow fibrosis, and the absence of organomegaly. Acute myelofibrosis in patients with acute lymphoblastic leukemia is extremely rare.
Namık Özbek +5 more
doaj
Veterinary Medicine and Science, Volume 12, Issue 2, March 2026.ABSTRACT Precursor‐targeted immune‐mediated anaemia (PIMA) is an uncommon and poorly understood cause of persistent non‐regenerative anaemia in dogs and cats, characterised by ineffective erythropoiesis and frequently associated with rubriphagocytosis (RP) in bone marrow samples.
Souad Nasar +7 more
wiley +1 more source
European Journal of Haematology, Volume 116, Issue 3, Page 302-310, March 2026.ABSTRACT Since 2004, patients receiving imatinib with relapse in non‐marrow sites were given dasatinib to preserve control of leukemic marrow. Remissions in CNS and other organs began to be reported and are continuously observed to present. With resistance to one BCR::ABL1 tyrosine kinase inhibitor and sensitivity to a dual BCR::ABL1/SRC inhibitor ...
I. Cunningham +4 more
wiley +1 more source
Clinical Outcomes of Ruxolitinib Treatment in Patients With IPSS Intermediate‐1‐Risk Myelofibrosis: Interim Analysis From an Italian, Prospective Study (ROMEI) [PDF]
Hematol OncolABSTRACT Ruxolitinib (RUX), a JAK1/2 inhibitor, demonstrated treatment benefits for myelofibrosis (MF) in intermediate‐1 (Int‐1)–risk patients with a significant disease burden; however, the evidence is scarce. This interim analysis investigated the efficacy and safety of ruxolitinib in patients with Int‐1‐risk MF.
Guglielmelli P +51 more
europepmc +2 more sources